Proje Geliştirme ve
Koordinasyon Birimi

2016-02-08 Spain: TLR-Based Immune Adjuvants for Vaccines Against Neglected Infectious Diseases


 

 TLR-Bsased Immune Adjuvants for Vaccines Against Neglected Infectious Disease


Description of the project offered: 
Spanish Biotech Company Diomune SL is seeking for a partner interested in being part of a proposal in the H2020 program, topic SC1-PM-06-2016 "Vaccine development for malaria and/or neglected infectious diseases". The aim of the proposed project is to use new powerful adjuvants able to modulate the different T helper lymphocyte responses to tailor/enhance the correct immune protective response triggered by antigens against infectious neglected diseases.

Modern vaccines (based on antigenic subunits), are safer than older style live or killed whole organism vaccines, but are also far less immunogenic, highlighting the need to develop better adjuvants. Effective vaccines are urgently needed for many diseases caused by intracellular pathogens including many neglected diseases such as Leishmaniasis, Malaria, Chagas, and Toxoplasmosis. These intracellular parasites are well-adapted pathogens with complexes mechanisms for evading immune responses. Moreover, different types of adaptative immune responses need to be induced to generate protective immunity against different parasites. Thus, the development of novel and sophisticated adjuvants with the ability of modulating different parameters of immune responses including specificity, type, intensity, duration and genetic variability, is an urgent need.

The importance of TLR agonists or ligands as therapeutic drugs for infectious diseases is becoming increasingly evident. TLRs are required for initiating the immune response against all pathogens and are involved in the control of the type of immune response induced. Spanish Biotech Company Diomune SL has extensive experience in the study of infectious, inflammatory and autoimmune diseases. We are specialized on the research of new Toll-Like Receptors (TLR) ligands and on the development of novel compounds with different immunomodulatory profiles and adjuvant properties. We are interested in investigating the synergistic effect of potential vaccine adjuvants developed by our company with parasite antigens to generate better and safer vaccines. The main goals will be to (i) enhance the immunogenicity of recombinant antigens used as vaccine candidates; (ii) reduce the amount of antigen or the number of immunizations needed for protective immunity (iii) induce the correct type of protective Immune Responses.

We are looking for partners belonging to public/private research institutions, universities, research hospitals, biotechnological companies, and industrial pharma dedicated to the development of new vaccines against malaria and/or other neglected infectious diseases.

We anticipate that our immunomodulatory compounds combined with a suitable antigen, will be able to induce an early, potent and long lasting specific immune response. We expect this project will lead to promising vaccine adjuvant formulations for the treatment of one or several neglected infectious diseases, particularly in poorer developing countries. 

You can find more information about our Research in www.diomune.com

The call deadline is 13rd April 2016. 
Link to the call: http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/3052-sc1-pm-06-2016.html
Project proposer:   Laura Córdoba ()
Partner role:  Project participant 
Partner organisation:  Research
Call for proposal title:  Personalised Medicine 
Call for proposal identifier:  H2020-SC1-2016-2017


Description of the collaboration sought: 
We are looking for partners belonging to public/private research institutions, universities, research hospitals, biotechnological companies, and industrial pharma dedicated to the development of new vaccines against malaria and/or other neglected infectious diseases.
We are seeking for partners with expertise in the following categories:

- Basic Laboratory Research groups specialized in the study of neglected diseases such as Malaria, Leishmaniasis, Chagas and Toxoplasmosis, and devoted to the identification of vaccine candidate antigens for these pathogens.

- Pharmaceutical Laboratories accredited with Good Manufacturing Practices (GMP) for large scale vaccine production, vaccine formulation, analytical testing (characterization and lot release), and capable of transferring successful candidates to partner organizations for eventual commercialization. 
Expertise sought: Life sciences, Biotechnology, Medicine. Health, Industrial biotech, 
Roles sought: Project coordinator, Project participant, 
Organisation types sought: 
Countries sought: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom, 

Call for proposal specific information
The referenced call for proposals has no specific fields defined.